Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates
Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.